10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications

10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications

Independent Study Guide Notice: Independent study guide by OpenExamPrep. This educational resource is developed independently by OpenExamPrep and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Catecholamine Biosynthesis, Storage, Release & Termination

Adrenergic transmission is mediated by endogenous catecholamines: Dopamine, Norepinephrine (Noradrenaline), and Epinephrine (Adrenaline). Understanding their biochemical pathway is essential for interpreting sympathomimetic and sympatholytic pharmacology.

Biosynthetic Pathway

1. L-Tyrosine $\rightarrow$ L-DOPA: L-Tyrosine is transported into adrenergic nerve terminals and hydroxylated to L-Dihydroxyphenylalanine (L-DOPA) by the cytosolic enzyme Tyrosine Hydroxylase (TH). This step requires molecular oxygen and tetrahydrobiopterin ($BH_4$) and represents the absolute rate-limiting step in catecholamine synthesis.
2. L-DOPA $\rightarrow$ Dopamine: L-DOPA is rapidly decarboxylated to Dopamine by DOPA Decarboxylase (Aromatic L-amino acid decarboxylase), utilizing pyridoxal phosphate (Vitamin $B_6$) as a cofactor.
3. Dopamine $\rightarrow$ Norepinephrine: Dopamine is transported into synaptic storage vesicles by the Vesicular Monoamine Transporter (VMAT-2). Inside the vesicle, Dopamine $\beta$-Hydroxylase (DBH) hydroxylates dopamine to Norepinephrine (NE). This step requires Vitamin C (ascorbate) and copper.
4. Norepinephrine $\rightarrow$ Epinephrine: In the adrenal medulla (and certain central adrenergic neurons), norepinephrine exits the vesicle and is methylated to Epinephrine by Phenylethanolamine N-Methyltransferase (PNMT) in the cytosol, utilizing S-adenosylmethionine (SAM) as a methyl donor. Synthesis of PNMT is heavily upregulated by cortisol delivered directly via intra-adrenal portal blood flow from the adrenal cortex.

                                Catecholamine Synthesis
   L-Tyrosine
       │
       ▼ [Tyrosine Hydroxylase] (Rate-Limiting Step; BH4 dependent)
    L-DOPA
       │
       ▼ [DOPA Decarboxylase] (Vitamin B6 dependent)
    Dopamine
       │
       ▼ [Dopamine β-Hydroxylase] (Inside Storage Vesicle; Ascorbate dependent)
  Norepinephrine
       │
       ▼ [PNMT] (Adrenal Medulla only; Upregulated by Cortisol)
   Epinephrine

Storage, Release & Termination of Transmission

• Vesicular Storage & Reserpine: Catecholamines are concentrated inside vesicles via VMAT-2. The antihypertensive alkaloid Reserpine irreversibly inhibits VMAT-2, leaving cytosolic catecholamines unprotected against enzymatic degradation, thereby depleting presynaptic stores.
• Exocytosis: Presynaptic depolarization opens N-type voltage-gated calcium channels; calcium influx triggers SNARE-mediated vesicular fusion and exocytosis of NE and ATP into the synaptic cleft.
• Presynaptic Reuptake (NET / Uptake-1): In sharp contrast to acetylcholine, approximately $80\% - 90\%$ of synaptic norepinephrine is terminated by active presynaptic reuptake via the sodium-dependent Norepinephrine Transporter (NET-1). Drugs that block NET—notably Cocaine and Tricyclic Antidepressants (TCAs)—prevent catecholamine clearance, intensely potentiating sympathetic actions.
• Enzymatic Degradation (MAO & COMT): Un-recycled catecholamines are degraded by two principal enzymes:
  • Monoamine Oxidase (MAO): Located on the outer mitochondrial membrane of neurons and liver. MAO-A degrades NE, epinephrine, and serotonin ($5\text{-HT}$); MAO-B selectively degrades dopamine.
  • Catechol-O-Methyltransferase (COMT): Located in the cytoplasm of post-synaptic tissues and liver; transfers a methyl group from SAM.
  • End-Stage Metabolite: The final common hepatic and renal breakdown product of norepinephrine and epinephrine is Vanillylmandelic Acid (VMA), along with intermediate metanephrines and normetanephrines. Measurement of 24-hour urinary metanephrines and VMA serves as the premier diagnostic test for pheochromocytoma.

Adrenergic Receptor Taxonomy & Second Messenger Cascades

All adrenergic receptors are seven-transmembrane G-protein-coupled receptors (GPCRs). They are categorized into Alpha ($\alpha_1, \alpha_2$) and Beta ($\beta_1, \beta_2, \beta_3$) classes.

Sympathomimetic Agonists: Clinical Profiles

                         Adrenergic Agonist Hemodynamics
   Agent          Primary Receptors       Heart Rate (HR)        Blood Pressure (MAP)
   ─────────────────────────────────────────────────────────────────────────────
   Epinephrine    α1, α2, β1, β2          ↑ (Direct β1)          ↑ (High dose) / ↔ (Low)
   Norepinephrine α1 > β1                 ↓ (Reflex Bradycardia) ↑↑ (Intense Vasoconstriction)
   Isoproterenol  β1 = β2                 ↑↑ (Direct β1 + Reflex) ↓ (Profound Vasodilation)
   Phenylephrine  Pure α1                 ↓↓ (Reflex Bradycardia) ↑↑ (Vasoconstriction)

Epinephrine (Adrenaline)

• Receptor Selectivity: Non-selective agonist; binds $\alpha_1, \alpha_2, \beta_1, \beta_2$.
• Dose-Dependent Hemodynamics:
  • Low Doses ($0.01 - 0.05\text{ mcg/kg/min}$): Selective for $\beta_1$ and $\beta_2$ receptors. Increases heart rate and stroke volume ($\beta_1$), while dilating skeletal muscle vascular beds ($\beta_2$). Systolic blood pressure rises while diastolic pressure decreases, resulting in widened pulse pressure with little change in mean arterial pressure (MAP).
  • High Doses ($> 0.1\text{ mcg/kg/min}$): $\alpha_1$ vasoconstrictor actions dominate over $\beta_2$ vasodilation, resulting in marked systemic vasoconstriction, elevated SVR, and elevated systolic and diastolic blood pressure.
• Clinical Indications:
  • Anaphylactic Shock: First-line emergency drug ($0.3 - 0.5\text{ mg}$ IM in anterolateral thigh). Reverses life-threatening laryngeal edema and hypotension ($\alpha_1$), reverses bronchospasm and inhibits mast cell degranulation ($\beta_2$), and supports cardiac contractility and output ($\beta_1$).
  • Cardiopulmonary Resuscitation (ACLS): $1\text{ mg}$ IV every 3–5 minutes during cardiac arrest.
  • Local Anesthetic Additive in Podiatric Surgery: Added at concentrations of $1:100,000$ or $1:200,000$ to lidocaine or bupivacaine.

Norepinephrine (Noradrenaline)

• Receptor Selectivity: Potent $\alpha_1 > \alpha_2 > \beta_1$ agonist; negligible affinity for $\beta_2$.
• Hemodynamic Profile: Induces intense systemic vasoconstriction in all vascular beds, markedly increasing Systemic Vascular Resistance (SVR), systolic BP, and diastolic BP. Although norepinephrine directly stimulates cardiac $\beta_1$ receptors, the rapid surge in mean arterial pressure activates high-pressure carotid sinus and aortic arch baroreceptors. The resulting compensatory vagal parasympathetic discharge overrides direct $\beta_1$ chronotropic effects, producing Reflex Bradycardia accompanied by high stroke volume.
• Clinical Use: First-line vasopressor of choice for septic shock and refractory vasodilatory shock.

Other Clinically Significant Sympathomimetics

• Dopamine: Exerts dose-dependent receptor activation:
  • Low dose ($1 - 2\text{ mcg/kg/min}$): Binds vascular $D_1$ receptors in renal, mesenteric, and coronary beds, stimulating adenylyl cyclase to promote renal vasodilation.
  • Intermediate dose ($2 - 10\text{ mcg/kg/min}$): Stimulates cardiac $\beta_1$ receptors, increasing inotropy and cardiac output.
  • High dose ($> 10\text{ mcg/kg/min}$): Stimulates vascular $\alpha_1$ receptors, causing generalized vasoconstriction and elevating blood pressure.
• Dobutamine: Selective $\beta_1 > \beta_2 > \alpha_1$ agonist. Potent inotrope that increases cardiac contractility and stroke volume with minimal chronotropic effect; produces mild $\beta_2$ vasodilation that reduces afterload. Used in cardiogenic shock and pharmacological cardiac stress testing.
• Phenylephrine: Pure selective $\alpha_1$ agonist (zero beta activity). Produces profound vasoconstriction, sharp increase in SVR and BP, and dramatic reflex bradycardia. Used as a topical nasal decongestant, mydriatic, and intravenous vasopressor for hypotension during spinal/general anesthesia.
• Isoproterenol: Non-selective $\beta_1 = \beta_2$ agonist (zero alpha activity). Stimulates cardiac $\beta_1$ (profound tachycardia and increased contractility) while stimulating vascular $\beta_2$ (intense skeletal muscle vasodilation, dropping diastolic BP and SVR). MAP falls, triggering additional reflex tachycardia.
• Central $\alpha_2$ Agonists (Clonidine & Methyldopa):
  • Clonidine: Stimulates central presynaptic $\alpha_2$ receptors in the rostral ventrolateral medulla and nucleus tractus solitarius, reducing sympathetic outflow to the heart and vascular tree, lowering blood pressure and heart rate. Rebound Hypertensive Crisis: Abrupt cessation of chronic clonidine triggers a massive surge of catecholamines acting on up-regulated postsynaptic receptors, causing severe rebound hypertension, tachycardia, and stroke. Clonidine must always be tapered gradually.
  • Methyldopa: Converted in the brain to $\alpha$-methylnorepinephrine, activating central $\alpha_2$ receptors. First-line antihypertensive in pregnancy (safe for fetus). Adverse effect: Direct Coombs-positive autoimmune hemolytic anemia.
• Short- and Long-Acting $\beta_2$ Agonists (Albuterol, Salmeterol): Relax bronchial smooth muscle in asthma and COPD. Adverse effects: fine skeletal muscle tremor ($\beta_2$ mediated), reflex tachycardia, and transient hypokalemia ($\beta_2$ stimulates $Na^+/K^+$ ATPase, driving potassium into skeletal muscle cells; utilized therapeutically for emergency hyperkalemia management).

Sympatholytic Agents: Alpha & Beta Adrenergic Antagonists

Alpha-Adrenergic Receptor Blockers

Beta-Adrenergic Receptor Blockers

Beta-blockers competitive antagonize catecholamine binding at $\beta_1$ and $\beta_2$ receptors.

Pharmacologic Classification of Beta-Blockers

Podiatric & Systemic Adverse Consequences

1. Cardiovascular: Sinus bradycardia, AV conduction block (contraindicated in 2nd/3rd degree AV block), acute exacerbation of decompensated heart failure.
2. Pulmonary Bronchoconstriction: Blockade of bronchial $\beta_2$ receptors prevents smooth muscle relaxation. In patients with asthma or severe COPD, non-selective beta-blockers can precipitate lethal status asthmaticus. When a beta-blocker is mandatory in a patient with reactive airway disease, a cardioselective $\beta_1$ blocker (e.g., metoprolol or bisoprolol) must be selected with extreme caution.
3. Peripheral Vascular Exacerbations in Podiatry: In patients with severe Peripheral Artery Disease (PAD) or Raynaud Phenomenon, non-selective beta-blockade eliminates physiological $\beta_2$-mediated skeletal muscle vasodilation. This leaves systemic vascular $\alpha_1$ receptors unopposed, precipitating severe peripheral digital vasoconstriction, cold extremities, ischemic digital pain, and delayed surgical wound healing.
4. Masking of Hypoglycemia in Diabetics: Hypoglycemia triggers a compensatory surge of epinephrine that stimulates $\beta_1$ and $\beta_2$ receptors, warning the patient through diaphoresis, tachycardia, palpitations, tremors, and anxiety. Beta-blockers blunt the warning signs of tachycardia and tremor, allowing severe neuroglycopenic hypoglycemia to progress undetected into seizures or coma. Notably, diaphoresis (sweating) is mediated by sympathetic cholinergic $M_3$ receptors and is NOT blocked by beta-blockers, remaining the sole reliable warning sign of hypoglycemia!

Beta-Blocker Overdose & Glucagon Rescue

Beta-blocker toxicity presents with profound sinus bradycardia, hypotension, AV block, cardiogenic shock, and central nervous system depression.

• Treatment:
  • Initial IV atropine and isotonic fluids (frequently ineffective in massive overdose).
  • Definitive Pharmacologic Antidote: Intravenous Glucagon.
  • Mechanism of Glucagon: Glucagon binds to independent G-protein-coupled glucagon receptors on cardiac myocyte membranes that couple to $G_s$. This bypasses the blocked $\beta$-adrenergic receptors entirely, stimulating adenylyl cyclase to elevate intracellular cyclic AMP ($cAMP$). Increased cAMP activates PKA, enhancing intracellular calcium influx to restore myocardial contractility (positive inotropy) and heart rate (positive chronotropy).